In addition to illustrating mycolactone’s ability to efficiently block mouse Sec61, these data revealed the potential interest of Sec61 inhibitors for the treatment of B‐ALL, and potentially other proteasome inhibition‐susceptible malignancies. Here, SEC61A1 is linked to precursor B-cell acute lymphoblastic leukemia.